Fintel reports that on August 31, 2026, Cantor Fitzgerald initiated coverage of Braveheart Bio (NASDAQGM:BRVE) with a Overweight recommendation. This coverage initiation by Cantor Fitzgerald was part ...

Fintel reports that on August 31, 2026, Goldman Sachs initiated coverage of Braveheart Bio (NASDAQGM:BRVE) with a Buy recommendation. This rating action was officially recorded on August 31, 2026, for ...

Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its ...

Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, ...

Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.

Braveheart Bio is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for the treatment of hypertrophic cardiomyopathy, with its lead product candidate BHB-1839, a ...

Insiders are buying shares of Braveheart Bio, BlossomHill Therapeutics and Elanco, three health care stocks with differing ...

Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, ...

A new trailer for Braveheart 2 starring Mel Gibson has just been released, creating a buzz online. The trailer shows a plot that delves into a new chapter of the story set up in the original film. Now ...